Open AccessRole of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
Author(s) -
Abu Taiub Mohammed Mohiuddin Chowdhury,
Aktar Kamal,
Md. Kafil Uddin Abbas,
Md. Rezaul Karim,
Md. Ahsan Ali,
Shubhashis Talukder,
Hasan Mehedi,
Hamid Hassan,
Abul Hossain Shahin,
Yarui Li,
Shuixiang He
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i23.8170
Subject(s) - medicine , famotidine , intensive care unit , randomized controlled trial , randomization , population , mortality rate , covid-19 , disease , environmental health , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) is a global pandemic putting the population at a high risk of infection-related health hazards, mortality and a potential failure of proper medical therapies. Therefore, it is necessary to evaluate the potential use of the existing drugs that could be used as options for the medical management of COVID-19 patients.